Literature DB >> 7722997

Issues in the development of client-treatment matching hypotheses.

R Longabaugh1, P W Wirtz, C C DiClemente, M Litt.   

Abstract

This article discusses observations and insights that were gained in the course of critiquing the a priori client-treatment matching hypothesis that were developed for Project MATCH. A matching taxonomy is offered that differentiates eight types of ordinal and disordinal interactions and discusses their clinical and substantive implications. Previously reported alcohol treatment studies are used to illustrate many of these. Various issues in matching studies, such as power versus complexity, prediction versus explanation, matches versus mismatches and capitalization versus compensation, are discussed. Selective issues in choosing treatment and client-matching variables as they affect matching hypotheses are also addressed. The importance of developing a putative "causal chain" for testing the theory underlying matching processes is explicated and a procedure for testing this causal chain is outlined.

Entities:  

Mesh:

Year:  1994        PMID: 7722997     DOI: 10.15288/jsas.1994.s12.46

Source DB:  PubMed          Journal:  J Stud Alcohol Suppl        ISSN: 0363-468X


  4 in total

Review 1.  Family-based therapy for adolescent drug abuse: knowns and unknowns.

Authors:  T J Ozechowski; H A Liddle
Journal:  Clin Child Fam Psychol Rev       Date:  2000-12

2.  Network support for drinking: an application of multiple groups growth mixture modeling to examine client-treatment matching.

Authors:  Johnny Wu; Katie Witkiewitz
Journal:  J Stud Alcohol Drugs       Date:  2008-01       Impact factor: 2.582

3.  Profiles of confidence and commitment to change as predictors of moderated drinking: a person-centered approach.

Authors:  Alexis Kuerbis; Stephen Armeli; Frederick Muench; Jon Morgenstern
Journal:  Psychol Addict Behav       Date:  2014-08-18

4.  Compliance and hypertension.

Authors:  F B Garfield; J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.